The 18th Meeting of the International Society of Amyloidosis was held in Heidelberg, Germany, from September 4-8. This meeting brought together experts as they discussed novel therapies, clinical trial updates, and the diagnosis and management of amyloidosis.
View all videos

ISA 2022

The 18th Meeting of the International Society of Amyloidosis
04–08 September 2022 | Heidelberg, Germany / Online
Retweet on TwitterVJHemOnc Retweeted
MosqueraOrgeiraAdrián Mosquera Orgueira@MosqueraOrgeira·
2h

It was an absolute pleasure to talk with our friends from @VJHemOnc about the non-for-profit AI solutions that we are developing to extend precise prognostication in MF and MDS to all healthcare systems. @ASH_hematology #GEMFIN @gesmd @_pethema @idis_research https://twitter.com/VJHemOnc/status/1621418665609412609

VJHemOnc@VJHemOnc

🚨 Want to learn more about the application of AI and machine learning in myelofibrosis prognostication?

Check out our interview with @MosqueraOrgeira below:

👉http://ow.ly/zJYI50MzXgg👈

@ASH_hematology #ASH22 #MPNsm #HemOnc #AI

Reply on Twitter 1621464807479058436Retweet on Twitter 16214648074790584361Like on Twitter 16214648074790584363View Tweet 1621464807479058436
VJHemOncVJHemOnc@VJHemOnc·
2h

This year's #ASH22 meeting brought so many updates in multiple myeloma, including novel CAR-T therapies, BiTEs, trial updates, and more!

To stay up-to-date with the latest, visit our post-ASH virtual workshop on-demand content:

👉http://ow.ly/jhhB50MHyo6👈

#MMsm #ImmunoOnc

Reply on Twitter 1621463817325608962Retweet on Twitter 16214638173256089621Like on Twitter 1621463817325608962View Tweet 1621463817325608962
VJHemOncVJHemOnc@VJHemOnc·
5h

🚨 Want to learn more about the application of AI and machine learning in myelofibrosis prognostication?

Check out our interview with @MosqueraOrgeira below:

👉http://ow.ly/zJYI50MzXgg👈

@ASH_hematology #ASH22 #MPNsm #HemOnc #AI

Reply on Twitter 1621418665609412609Retweet on Twitter 1621418665609412609Like on Twitter 16214186656094126091View Tweet 1621418665609412609
VJHemOncVJHemOnc@VJHemOnc·
17h

📣 Check out our latest weekly podcast, where you will hear from experts @mike_dickinson1 & Tycel Phillips (@LymphClinician), who share their highlights in NHL at #ASH22:

🎧: http://ow.ly/5whs50MHIP4

#LymSM #HemOnc #ImmunoOnc

Reply on Twitter 1621237708730294277Retweet on Twitter 16212377087302942771Like on Twitter 1621237708730294277View Tweet 1621237708730294277
Retweet on TwitterVJHemOnc Retweeted
Dr_AmerZeidanAmer Zeidan MBBS,MHS ‏عامر زيدان@Dr_AmerZeidan·
20h

Each time I read an #AMLsm paper report morphological leukemia free state (MLFS) as a response criterion I cringe! While MLFS is listed in ELN criteria, it is not validated as proxy for long term benefit & does not reflect meaningful short term benefit to patients! Do you agree?

Reply on Twitter 1621194305040941056Retweet on Twitter 16211943050409410562Like on Twitter 16211943050409410568View Tweet 1621194305040941056
Load More...

ISA 2022

The 18th Meeting of the International Society of Amyloidosis
04–08 September 2022 | Heidelberg, Germany / Online
The 18th Meeting of the International Society of Amyloidosis was held in Heidelberg, Germany, from September 4-8. This meeting brought together experts as they discussed novel therapies, clinical trial updates, and the diagnosis and management of amyloidosis.
View all videos
Retweet on TwitterVJHemOnc Retweeted
MosqueraOrgeiraAdrián Mosquera Orgueira@MosqueraOrgeira·
2h

It was an absolute pleasure to talk with our friends from @VJHemOnc about the non-for-profit AI solutions that we are developing to extend precise prognostication in MF and MDS to all healthcare systems. @ASH_hematology #GEMFIN @gesmd @_pethema @idis_research https://twitter.com/VJHemOnc/status/1621418665609412609

VJHemOnc@VJHemOnc

🚨 Want to learn more about the application of AI and machine learning in myelofibrosis prognostication?

Check out our interview with @MosqueraOrgeira below:

👉http://ow.ly/zJYI50MzXgg👈

@ASH_hematology #ASH22 #MPNsm #HemOnc #AI

Reply on Twitter 1621464807479058436Retweet on Twitter 16214648074790584361Like on Twitter 16214648074790584363View Tweet 1621464807479058436
VJHemOncVJHemOnc@VJHemOnc·
2h

This year's #ASH22 meeting brought so many updates in multiple myeloma, including novel CAR-T therapies, BiTEs, trial updates, and more!

To stay up-to-date with the latest, visit our post-ASH virtual workshop on-demand content:

👉http://ow.ly/jhhB50MHyo6👈

#MMsm #ImmunoOnc

Reply on Twitter 1621463817325608962Retweet on Twitter 16214638173256089621Like on Twitter 1621463817325608962View Tweet 1621463817325608962
VJHemOncVJHemOnc@VJHemOnc·
5h

🚨 Want to learn more about the application of AI and machine learning in myelofibrosis prognostication?

Check out our interview with @MosqueraOrgeira below:

👉http://ow.ly/zJYI50MzXgg👈

@ASH_hematology #ASH22 #MPNsm #HemOnc #AI

Reply on Twitter 1621418665609412609Retweet on Twitter 1621418665609412609Like on Twitter 16214186656094126091View Tweet 1621418665609412609
VJHemOncVJHemOnc@VJHemOnc·
17h

📣 Check out our latest weekly podcast, where you will hear from experts @mike_dickinson1 & Tycel Phillips (@LymphClinician), who share their highlights in NHL at #ASH22:

🎧: http://ow.ly/5whs50MHIP4

#LymSM #HemOnc #ImmunoOnc

Reply on Twitter 1621237708730294277Retweet on Twitter 16212377087302942771Like on Twitter 1621237708730294277View Tweet 1621237708730294277
Retweet on TwitterVJHemOnc Retweeted
Dr_AmerZeidanAmer Zeidan MBBS,MHS ‏عامر زيدان@Dr_AmerZeidan·
20h

Each time I read an #AMLsm paper report morphological leukemia free state (MLFS) as a response criterion I cringe! While MLFS is listed in ELN criteria, it is not validated as proxy for long term benefit & does not reflect meaningful short term benefit to patients! Do you agree?

Reply on Twitter 1621194305040941056Retweet on Twitter 16211943050409410562Like on Twitter 16211943050409410568View Tweet 1621194305040941056
Load More...

Latest Videos

View all
4:18
Considerations for transplantation in AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
1:47
Current and emerging antibody-based immunotherapies in AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
2:38
Unmet needs in imaging for the diagnosis of AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
3:05
Sensitive detection of TTR aggregates for early diagnosis and monitoring of ATTR amyloidosis
Lorena Saelices • 7 Sep 2022

AL Amyloidosis

View all
4:18
Considerations for transplantation in AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
1:47
Current and emerging antibody-based immunotherapies in AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
2:38
Unmet needs in imaging for the diagnosis of AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
5:38
Insights into the pathogenesis of amyloidosis from the proteome of renal amyloid plaques
Charalampos Charalampous • 7 Sep 2022

ATTR Amyloidosis

View all
6:00
Association between the V122I TTR variant with heart failure in ATTR amyloidosis, SCD & leukemia
Kwaku Appiah-Kubi • 6 Sep 2022
3:51
Current diagnostic and management strategies for ATTR amyloidosis
Ramzi Tabbalat • 6 Sep 2022
2:58
The potential role of PET/CT imaging in the early diagnosis and monitoring of ATTR amyloidosis
Jonathan Wall • 14 Sep 2022
3:16
The potential of AT-02 as a therapeutic strategy in ATTR & AL amyloidosis
Jonathan Wall • 14 Sep 2022

Diagnosis

View all
2:38
Unmet needs in imaging for the diagnosis of AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
3:05
Sensitive detection of TTR aggregates for early diagnosis and monitoring of ATTR amyloidosis
Lorena Saelices • 7 Sep 2022

Treatment

View all
4:18
Considerations for transplantation in AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
1:47
Current and emerging antibody-based immunotherapies in AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022

Transplantation

View all
4:18
Considerations for transplantation in AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
1:29
The impact of clonal features on the survival of patients with non-cardiac AL amyloidosis
Paolo Milani • 7 Sep 2022

Immuno-Oncology

View all
1:47
Current and emerging antibody-based immunotherapies in AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
3:16
The potential of AT-02 as a therapeutic strategy in ATTR & AL amyloidosis
Jonathan Wall • 14 Sep 2022
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals